October 2026 vial prices from each country's official database — and why the generic nearly closed the gap.
Researched with AI assistance; every figure is checked against the primary source cited on this page before publishing. How we work →
Price of one 10 mL vial (1,000 units) of rapid-acting insulin, from each country's official source, converted to US dollars at European Central Bank reference rates of October 20, 2026. US figures are what pharmacies pay (CMS NADAC), not what an insured patient pays. The European figures are each system's official price level — the retail price including VAT in Switzerland, the social-insurance price excluding VAT in Austria, the average pharmacy price in the Netherlands — so they are not exactly like-for-like with the US acquisition cost. Germany has no official price for an insulin lispro vial.
| Country | Price per 10 mL vial | In US dollars | What a patient typically pays |
|---|---|---|---|
| 🇺🇸 United States (Humalog / Novolog) | $63.55 / $69.33 pharmacy cost | $64 / $69 | Depends on insurance; $35 a month on Medicare |
| 🇺🇸 United States (generic lispro) | $24.02 pharmacy cost | $24 | Depends on insurance |
| 🇬🇧 United Kingdom | £16.61 NHS price | $22 | Free for people with diabetes on insulin |
| 🇫🇷 France | €14.31 official price | $16 | Covered in full under the diabetes long-term condition (ALD) |
| 🇦🇺 Australia | PBS-subsidised | — | A$25 (about $17); A$7.70 with a concession card |
| 🇨🇭 Switzerland | CHF 38.65 official public price | $47 | Adults: first CHF 300 a year in full, then 10% up to CHF 700 a year |
| 🇦🇹 Austria | €27.28 (2-vial pack €54.55, excl. VAT) | $31 | €7.55 prescription fee per pack |
| 🇳🇱 Netherlands | €17.87 average pharmacy price | $20 | Reimbursed, but counts against the compulsory deductible (up to €385 in 2026) |
| Item | Figure | Context | Source |
|---|---|---|---|
| United States — brand | $63.55 Humalog · $69.33 Novolog / vial | CMS's NADAC survey (as of October 21, 2026) puts a 10 mL Humalog vial at $63.55 and a Novolog vial at $69.33 in pharmacy acquisition cost — after the 2023–24 list-price cuts. A Lantus vial runs $61.49. | CMS NADAC (Oct 21, 2026) |
| The catch — generic vs brand | $24.02 / vial (insulin lispro) | Unbranded insulin lispro costs US pharmacies $24.02 a vial — about the NHS price. What's left of the gap sits mostly between brand and generic, and between who pays: the federal $35-a-month cap covers only Medicare. | CMS NADAC (Oct 21, 2026) · federal law (2023) |
| United Kingdom | £16.61 / vial (≈ $22) | The NHS indicative price for a Humalog 10 mL vial has been £16.61 since February 1, 2009. People with diabetes treated with insulin qualify for free prescriptions in England through a medical exemption, and prescriptions are free in Scotland, Wales and Northern Ireland. | NHSBSA dm+d |
| France | €14.31 / vial (≈ $16) | France's public medicines database lists a Humalog 10 mL vial at €14.31 (€15.33 with the dispensing fee), reimbursed at 65%. Diabetes is a recognised long-term condition (ALD), under which related treatment is covered in full. | BDPM / ANSM (retrieved Oct 21, 2026) |
| Australia | A$25 per prescription (≈ $17) | On the PBS, a general patient pays at most A$25.00 per prescription from January 1, 2026, and concession-card holders A$7.70. | PBS / Department of Health (2026) |
| Production cost | $48–$133 per year | A peer-reviewed analysis estimated a full year's supply could be made — at a profit — for roughly $48–71 (human insulin) and under $133 (modern analogs). | BMJ Global Health (2018) |
| History — the 2018 gap | ~$99 / vial (2018) | RAND's study put the 2018 US manufacturer price near $99 a vial; in 2022 the US still paid about 9.7 times the average of 33 wealthy nations. The 2023–24 cuts changed that picture. | RAND (2018/2022 data) |
We compare what insulin costs, not what anyone should take, switch, or import. Drug decisions belong with you and a licensed prescriber.
Starting January 2023, a federal law capped insulin at $35 a month for everyone on Medicare, with no deductible — and the three big makers then cut their own list prices by roughly 70–78% and extended $35 caps to many people with private insurance. Millions got real relief, and an honest comparison has to say so as loudly as it says what follows.
The federal cap covers Medicare only, and applies only to insulins a plan actually covers; there is no federal cap for private insurance, and the uninsured rely on voluntary manufacturer programs. In 2018, before any caps, more than one in four insulin users on individual and small-group plans paid above $35 a month (KFF). A national survey published in Annals of Internal Medicine (2022) found that in 2021 about 1 in 6 US insulin users (16.5%) had skipped, delayed or stretched doses to save money — a cost data point that explains why this price gap is a life-or-death topic in a way most of our comparisons aren't.
Personal importation of prescription drugs is sharply restricted under US law. And the famous ten-times gap is the gross list-price picture: net of the rebates manufacturers quietly hand back, the US still paid about 2.3 times what other wealthy nations pay. The gap is real at either number — but honest journalism quotes both.
As of October 2026, a 10 mL Humalog vial costs US pharmacies $63.55 and generic insulin lispro $24.02 (CMS NADAC). The NHS price for the same Humalog vial is £16.61, about $22, and France lists it at €14.31, about $16. In 2022, before the big price cuts, the US paid about 9.7 times the average of 33 wealthy nations (RAND).
In Australia a general patient pays at most A$25 (about $17) per PBS prescription in 2026, or A$7.70 with a concession card. In the US a 10 mL Humalog vial costs pharmacies $63.55 and generic lispro $24.02 (NADAC, October 2026); what a patient pays depends on insurance, and Medicare caps it at $35 a month.
Far less than it sells for. Insulin is a roughly 100-year-old drug, and a peer-reviewed BMJ Global Health analysis estimated a full year's supply could be produced at a profit for about $48–71 for human insulin, and under $133 for modern analogs. The price reflects the pricing system, not the chemistry.
It changed a lot — for Medicare. Since January 2023, federal law caps insulin at $35 a month for Medicare beneficiaries, and the three big makers cut list prices by 70–78% and extended caps to many privately insured patients. But the federal cap covers only Medicare — there is no federal cap for private insurance. In 2018, before any caps, more than 1 in 4 insulin users on individual and small-group plans paid above $35 a month (KFF), and the uninsured still rely on voluntary programs.
No — it's the same modern analog insulin from the same makers. The only structural difference is that those countries negotiate a single national price, which the US, until very recently, didn't.
Personally importing prescription drugs is sharply restricted under US law, so it's rarely the clean shortcut it sounds like. And the famous ten-times gap needs an honest asterisk: it's the gross list-price gap. Net of rebates and discounts, the US still paid about 2.3× other wealthy nations — real, but not the frozen 10× of the headlines.
A national survey published in Annals of Internal Medicine (2022) found that in 2021 about 1 in 6 US insulin users (16.5%) had skipped, delayed or stretched doses to save money — presented here strictly as a cost data point, not guidance. Treatment decisions belong with a licensed prescriber.
Wellness Vision does not sell medication, book trips, or receive referrals of any kind. The data comes from the public sources cited above. This is a cost comparison, not medical advice — nothing here tells anyone to start, stop, switch, or import a medication.
📋 Or get the free Medical Travel Cost Checklist — no email →
View provenance manifest for this video →
You shouldn't have to go broke to feel whole.
